1. Home
  2. EVGO vs ZNTL Comparison

EVGO vs ZNTL Comparison

Compare EVGO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGO

EVgo Inc.

HOLD

Current Price

$1.59

Market Cap

249.7M

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$4.10

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGO
ZNTL
Founded
2010
2014
Country
United States
United States
Employees
376
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.7M
289.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EVGO
ZNTL
Price
$1.59
$4.10
Analyst Decision
Buy
Buy
Analyst Count
8
5
Target Price
$5.23
$6.60
AVG Volume (30 Days)
3.6M
1.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.45
N/A
Revenue Next Year
$29.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.41
$1.21
52 Week High
$5.18
$6.95

Technical Indicators

Market Signals
Indicator
EVGO
ZNTL
Relative Strength Index (RSI) 45.26 40.65
Support Level $1.41 $3.53
Resistance Level $2.30 $4.23
Average True Range (ATR) 0.12 0.39
MACD 0.01 -0.08
Stochastic Oscillator 48.61 6.58

Price Performance

Historical Comparison
EVGO
ZNTL

About EVGO EVgo Inc.

EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: